Anúncio
Anúncio

MRKR

MRKR logo

Marker Therapeutics, Inc. Common Stock

2.01
USD
Patrocinado
-0.06
-2.80%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

2.04

+0.03
+1.64%

Relatórios de Lucros MRKR

Rácio de surpresa positiva

MRKR separação 18 de 26 últimas estimativas.

69%

Próximo Relatório

Data do Próximo Relatório
30 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$695.64K
/
-$0.20
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-43.58%
/
+66.67%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-69.11%
/
-52.38%

Marker Therapeutics, Inc. Common Stock earnings per share and revenue

On 13 de nov. de 2025, MRKR reported earnings of -0.12 USD per share (EPS) for Q3 25, beating the estimate of -0.45 USD, resulting in a 73.86% surprise. Revenue reached 1.23 milhão, compared to an expected 737.46 mil, with a 67.20% difference. The market reacted with a +3.48% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analistas forecast an EPS of -0.20 USD, with revenue projected to reach 695.64 mil USD, implying an aumentar of 66.67% EPS, and diminuir of -43.58% in Revenue from the last quarter.
FAQ
For Q3 2025, Marker Therapeutics, Inc. Common Stock reported EPS of -$0.12, beating estimates by 73.86%, and revenue of $1.23M, 67.2% above expectations.
The stock price moved up 3.48%, changed from $0.89 before the earnings release to $0.92 the day after.
The next earning report is scheduled for 30 de mar. de 2026.
Based on 5 analistas, Marker Therapeutics, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $695.64K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio